News | December 22, 2011

ESC Calls for Studies Exploring Readmissions to Hospital Following PCI

December 22 2011 — A recent United States study on the importance of measuring rates of rehospitalization following percutaneous coronary intervention (PCI) has drawn the attention of the European Society of Cardiology (ESC). The research, published in the JACC Cardiovascular Interventions, represents one of the first studies to explore PCI readmissions. According to ESC, it highlights the need for similar studies to be initiated across Europe to improve patient care.

In the study, Edward Hannan, M.D., and colleagues from the School of Public Health at the University of New York, recorded hospital readmissions for 40,093 patients from New York State. All patients underwent their first PCI procedure between Jan. 1 and Nov. 30, 2007. The retrospective review found a total of 15.6 percent (6,254) of PCI patients were readmitted within 30 days; further analysis revealed that 20.6 percent (1,285) of these readmissions were “staged.” In staging, cardiologists treat the culprit lesion responsible for the initial admission; they then plan for patients to return to the hospital at a future date for treatment of additional lesions.

“Currently we’ve absolutely no idea of the number of patients in Europe who need readmission to hospitals after PCI,” said Prof. Eric Van Belle, an ESC spokesperson from the University of Lille, France. But the U.S. finding that 12.4 percent of PCI patients need to return for unplanned readmissions (not involving staging), he added, was much higher than predicted; to him, this highlighted the need for improvements in care.

 “To allow us to both prevent readmissions by tailoring care to individual patients and produce guidelines around which patients require staging, we need to gain a better handle on data in Europe,” Van Belle said.

Nevertheless, the question remains whether Europe has the infrastructure to identify patients who are likely to be readmitted to multiple hospitals. In the U.S. study, investigators acknowledged that principle diagnoses such as “chronic ischemic heart disease,” “atherosclerosis” and “chest pain” were not specific enough to determine the real reasons for admissions. This left doubts over whether the readmission had been necessitated by a complication of the index procedure or some separate event.

“Achieving a better understanding of the reasons why patients need unplanned admissions would help cardiologists learn how to target interventions to patients at greatest risk of complications,” said ESC spokesperson Prof. Hans Erik Bøtker, from Aarhus University, Skejby, Denmark.

Increased knowledge would also enable hospitals to be adequately reimbursed for the care. “Payments to hospitals could be adjusted to take into account factors such as co-morbidities that are likely to require additional care to prevent repeat hospitalization. The introduction of such systems would remove incentives for hospitals to discharge patients early,” said Bøtker.

The different health care reimbursement systems used in European countries, said Van Belle, influence whether hospitals offer “staged” readmissions. In some countries, hospitals are reimbursed with one fee for a fixed time period regardless of the number of individual procedures or different admissions; while in other countries a separate fee is paid for each admission. The former approach discourages use of staged procedures, while the later serves to encourage them. Both systems, argued Van Belle, can fail to take into account the clinical needs of individual patients.

“For each patient, a risk benefits analysis needs to be undertaken. For most people single procedures (where all the lesions are treated at the same time) carry less overall risks than multiple procedures. However, in certain circumstances when a great number of lesions need to be treated, staged care may be necessary to reduce excessive exposure to radiation,” said Van Belle.

Clearly, he added, evidence-based guidelines are needed to identify the patient groups who would benefit most from staged procedures. “We need to base our decisions on clinical evidence rather than being swayed by financial gain,” said Van Belle.

For more information: www.escardio.org

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init